Evidence-based indications for postmastectomy irradiation (Q35182953)

7 August 2017

1 reference

title

Evidence-based indications for postmastectomy irradiation (English)

1 reference

7 August 2017

Abram Recht

1

1 reference

7 August 2017

Stephen B Edge

series ordinal

2

1 reference

7 August 2017

publication date

1 August 2003

1 reference

Surgical Clinics of North America

7 August 2017

published in

1 reference

7 August 2017

volume

83

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

995-1013

1 reference

Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

The return (?) of postmastectomy radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Consensus Statement on postmastectomy radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Development and aftercare of clinical guidelines: the balance between rigor and pragmatism

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Rules of evidence and clinical recommendations on the use of antithrombotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM stage II. The South Sweden Breast Cancer Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Adjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Adjuvant radiotherapy and chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Postmastectomy radiotherapy: questions for the twenty-first century

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Local recurrence after mastectomy and adjuvant CMF: implications for adjuvant radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Local-regional recurrence in breast cancer after mastectomy and adriamycin-based adjuvant chemotherapy: evaluation of the role of postoperative radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Post-mastectomy radiotherapy in pT3N0M0 breast cancer: is it needed?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. II. 5-year results and influence of levamisole

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Locally advanced (noninflammatory) carcinoma of the breast: results and comparison of various treatment modalities

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Long-term results of post-operative radiation therapy following mastectomy with or without chemotherapy in stage I-III breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Local recurrence after simple mastectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

The role of mastectomy in patients with stage I-II breast cancer presenting with gross multifocal or multicentric disease or diffuse microcalcifications

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the Nationa

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer: a phase II trial of neoadjuvant MVAC, surgery, and radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. The German Breast-Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

A randomized trial of chemotherapy (L-PAM vs CMF) and irradiation for node positive breast cancer. Eleven year follow-up of a Piedmont Oncology Association trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Comparison of adjuvant postoperative radiotherapy and multiple-drug chemotherapy (CMF-VP) in operable breast cancer patients with more than four positive axillary lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900033-1

7 January 2021

10.1016/S0039-6109(03)00033-1

Identifiers

DOI

1 reference

7 August 2017

1 reference